Background: We investigated the pharmacokinetics (PK) of atazanavir/cobicistat and darunavir/cobicistat once daily over 72 h following drug intake cessation in plasma, saliva and urine.
Introduction
Ritonavir-boosted PIs such as atazanavir and darunavir have been used for many years and are an instrumental option as third agents in the management of HIV. 1 Advantages of pharmacological boosting include increased drug exposure and a prolonged half-life, thereby reducing pill burden, allowing once-daily dosing and, in the case of PIs, achieving a high genetic barrier to resistance. 2 The use of ritonavir as a boosting agent, however, presents a number of disadvantages. Consequently, cobicistat, a structural analogue without antiviral activity, is now available as an alternative pharmacokinetic (PK) enhancer. Unlike ritonavir, good solubility lends cobicistat to co-formulation and a lack of enzymeinducing activity potentially offers a better drug interaction profile. 3 It inhibits cytochrome P450 3A4 (CYP3A4) with a potency similar to that of ritonavir and, at a dosage of 150 mg once daily, provides bioequivalent exposures of atazanavir (300 mg once daily) and darunavir (800 mg once daily) 4 compared with those observed with 100 mg of ritonavir once daily. 3 We previously presented data on the PK forgiveness of oncedaily ritonavir-boosted darunavir and atazanavir, showing a favourable atazanavir PK tail and a slight increase in decline rate for both PIs as ritonavir concentrations decrease. 5 In vivo data for atazanavir/cobicistat and darunavir/cobicistat (both available in fixed-dose combination) concentration decay after intake cessation have not, however, been previously described.
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PIs as their use is increasingly targeted to complex cases of viral resistance, poor adherence and extensive antiretroviral treatment experience. 1 Drug persistence in plasma is dependent on its halflife (which itself depends on clearance and volume of distribution). 6 As such, antiretroviral agents with longer half-lives may be more forgiving and allow for forgotten doses, especially if drug concentrations remain therapeutic until the patient reinitiates drug intake.
In addition to the above, there is a paucity of data in the literature on PI exposure in other matrices such as saliva and urine, with one report available 7 and no study on drug levels in saliva or urine post-cessation of drug intake. Sampling of saliva and urine is significantly less invasive than venipuncture and therefore may be a valuable measure of adherence in clinical practice in future. This has been shown to be useful in other infectious diseases where long-term treatment, optimal drug absorption and adherence are fundamental, like TB, where urine colorimetry can detect low rifampicin plasma concentrations in HIV/TB co-infected individuals. 8 The object of this study was therefore to investigate the steadystate PK of atazanavir/cobicistat and darunavir/cobicistat oncedaily dosing over 72 h following drug intake cessation in plasma, saliva and urine.
Methods

Participants
Eligible participants were male and non-pregnant and non-lactating female healthy volunteers aged between 18 and 65 years with a BMI between 18 and 35 kg/m 2 . Participants were excluded if they had: any significant acute or chronic medical illness; abnormal physical examination, ECG or clinical laboratory determinations; positive screens for HIV, hepatitis B or C; current or recent (within 3 months) gastrointestinal disease; clinically relevant alcohol or drug use that the investigator felt would adversely affect compliance with trial procedures; exposure to any investigational drug or placebo within 3 months of the first dose of the study drug; use of any other drugs, including over-the-counter medications and herbal preparations, within 2 weeks of the first dose of the study drug; or previous allergy to any of the constituents of the pharmaceuticals administered during the trial.
Study design
This was an open-label, two-phase, 33 day PK trial carried out at the Clinical Trial Unit of the St Stephen's Centre, Chelsea and Westminster Hospital, London, UK.
At screening, participants had a clinical assessment and routine laboratory investigations performed. The safety and tolerability of study medications were evaluated throughout the trial (on days 1, 5, 10, 21, 25 and 30 and at follow-up) using the NIAID Division of AIDS table for grading the severity of adult and paediatric adverse events to characterize abnormal findings (published 2004), vital signs, physical examinations and clinical laboratory investigations. After successful screening, during the first study phase, volunteers were administered fixed-dose combination atazanavir/ cobicistat at 300/150 mg once daily (Evotaz V R ) in the morning for 10 days. On study days 10-13, atazanavir and cobicistat plasma concentrations were assessed pre-dose and at 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 48, 60 and 72 h post-dose. After a washout period of 10 days, all subjects were administered fixed-dose combination darunavir/cobicistat at 800/150 mg once daily (Rezolsta V R ) for 10 days. On study days 30-33, darunavir and cobicistat plasma concentrations were assessed pre-dose and at 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 48, 60 and 72 h post-dose. On the PK days, study medication intake with a standardized breakfast (626 kcal) and 240 mL of water was witnessed.
Analytical and PK methods
Blood samples were collected into lithium heparin-containing blood tubes (12 mL) at each timepoint, immediately inverted several times and then kept on ice or refrigerated until centrifugation. Within 30 min of blood collection, each blood sample was centrifuged for 10 min at 2000 g at 4
C. Plasma was then aliquoted equally into three 2.0 mL tubes (Sarstedt, Germany) and stored at #20 C. On the PK days, saliva (study subjects were asked to spit) and a minimum of 5 mL of urine were collected into universal containers at each scheduled sampling time (24, 30, 36, 48, 60 and 72 h post-dose).
Samples were shipped on dry ice to the Liverpool Bioanalytical Facility for analysis. The laboratory participates in an external quality assurance scheme (KKGT, The Netherlands).
Quantification of atazanavir, darunavir and cobicistat
Concentrations of atazanavir, darunavir and cobicistat in plasma, saliva and urine were measured using validated HPLC-tandem MS methods. 9 The lower limit of quantification (LLQ) for the plasma analyses was 10 ng/mL for atazanavir and cobicistat and 15 ng/mL for darunavir. For concentrations below the assay limit of quantification, a value of one-half of the quantification limit was used.
The saliva assay was validated over a calibration range of 3.7-500 ng/mL for all three analytes. Accuracy (percentage bias) was between 99.5% and 108.2% (atazanavir), 94.2% and 101.2% (darunavir) and 92.3% and 104.0% (cobicistat) and precision was between 2.8% and 5.4% (atazanavir), 4.4% and 6.0% (darunavir) and 3.1% and 6.5% (cobicistat).
Data analysis
The calculated PK parameters for plasma atazanavir, darunavir and cobicistat were the plasma concentration measured 24 h after the observed dose (C 24 ), the plasma C max and the plasma AUC 0-24 . The half-life was determined from the elimination phase within the normal dosing interval of 0-24 h and as a terminal elimination half-life to the last measurable concentration (C last ) within 72 h. All PK parameters were calculated using actual blood sampling time and non-compartmental modelling techniques (WinNonlin Phoenix, version 6.1; Pharsight, Mountain View, CA, USA). Descriptive statistics, including geometric mean (GM) and 95% CI were calculated for atazanavir, darunavir and cobicistat plasma PK parameters. GM values were compared with the suggested therapeutic targets that were established in vivo (atazanavir) and in vitro (darunavir) and are available in the current literature for each drug. 10, 11 These targets estimate the minimum effective concentration (MEC) to be equivalent to 10 times the protein-binding-corrected IC 50 for WT virus for atazanavir and for darunavir at 150 and 550 ng/mL, respectively.
Inter-individual variability in drug PK parameters was expressed as a percentage coefficient of variation [CV; (standard deviation/mean) % 100].
Urine and saliva concentrations were described as GM and 90% CI at each sampling timepoint over the concentration decay curves. Plasma drug concentrations were correlated to saliva and urine concentrations by linear regression analysis.
Ethics
The study protocol was approved by the Bloomsbury Research Ethics Committee Elliot et al.
Written informed consent was obtained from eligible participants after screening and counselling, on the same day.
Results
Study population
Sixteen volunteers completed all phases of the study. Median (range) age and BMI were 38 (24-54) years and 25 (22-31) kg/m 2 , respectively. Eight were female. Nine described themselves as Caucasians, six as black and one as Asian.
Atazanavir plasma PK
Atazanavir GM plasma concentration versus time curves when combined with cobicistat are shown in Figure 1 and PK parameters are summarized in Table 1 .
The GM terminal elimination half-life to 72 h of atazanavir was 6.77 h (95% CI 6.2-7.5). This value was lower than the half-life measured over the dosing interval of 24 h (GM 9.69 h; 95% CI 9.2-12.8).
All subjects had atazanavir concentrations above the suggested target 24 h post-dose (GM 759.2 ng/mL). Out of 16 subjects, 2 and 13 had concentrations below the target at 30 and 48 h postdose, respectively (GM 407.0 and 65.9 ng/mL; Table 2 ).
The inter-individual variability in atazanavir C 24 was 73%.
Darunavir plasma PK
Darunavir GM plasma concentration versus time curves when combined with cobicistat are shown in Figure 1 and PK parameters are summarized in Table 1 . Darunavir GM terminal elimination half-life was 6.4 h (95% CI 5.9-7.0). This value was lower than the half-life measured over the dosing interval of 24 h (GM 10.4 h; 95% CI 9.2-12.9).
Out of 16 subjects, 3 had darunavir concentrations below the suggested target 24 h post-dose and 11 had concentrations lower than the target at 30 h (GM 1032.6 and 381.7 ng/mL; Table 2 ).
The inter-individual variability in darunavir C 24 values was 65%.
Cobicistat plasma PK
Steady-state cobicistat PK parameters when combined with atazanavir and darunavir are reported in Table 3 . When combined with atazanavir, the GM terminal elimination half-life to the last measurable concentration for cobicistat was 4.2 h (95% CI 3.9-4.7) and over the dosing interval of 24 h was 4.4 h (95% CI 4.0-5.2).
These were higher than when cobicistat was combined with darunavir, where the GM terminal elimination half-life to the last measurable concentration was 3.6 h (95% CI 3.3-4.0) and over the dosing interval of 24 h was 3.8 h (95% CI 3.5-4.3).
Saliva and urine concentrations
GM saliva and urine concentrations measured between 24 and 72 h post-dose are illustrated in Figure 2 .
Although saliva concentrations of atazanavir and darunavir were lower than those measured in plasma (GM C 24 saliva:plasma ratios were 0.19 and 0.04, respectively), saliva PK profiles showed the same concentration decay trends of plasma.
On the other hand, urine concentrations were higher than in plasma, with urine:plasma ratios of 32.7 for atazanavir and 11.5 for darunavir.
Plasma-saliva correlation coefficients were R 2 " 0.533 for atazanavir and R 2 " 0.64 for darunavir. Plasma atazanavir concentrations correlated significantly with urine atazanavir concentrations (R 2 " 0.78). Plasma darunavir concentrations also correlated with urine darunavir (R 2 " 0.65), though the relationship did not appear as strong as for atazanavir. Atazanavir, darunavir and cobicistat pharmacokinetics
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Safety and tolerability
Treatment was generally well tolerated and no serious adverse events occurred during the study. As expected because extensively described in the literature, 12 the most common adverse events observed throughout the study were scleral icterus and hyperbilirubinaemia (during the atazanavir/cobicistat phase). No other clinically relevant changes in laboratory parameters were reported.
Discussion
We report for the first time the steady-state PK of atazanavir and darunavir in plasma, saliva and urine over 72 h following drug intake cessation in HIV-negative healthy volunteers to describe the PK forgiveness of these two commonly used PIs when boosted by cobicistat.
Concentrations of atazanavir were measurable in all subjects 48 h post-dose and in 11 and 2 subjects 60 and 72 h post-dose. Importantly 14/16 subjects had concentrations above the suggested MEC of 150 ng/mL and the remaining two had concentrations equal to 148 ng/mL 30 h post-dose, suggesting that a 6 h drug intake delay would not compromise optimal drug exposure and efficacy. Similarly, darunavir concentrations were measurable in 13/16, 6/16 and 2/16 subjects 48, 60 and 72 h post-dose, respectively. However, 3/16 study individuals had concentrations below the suggested 550 ng/mL cut-off 24 h post-dose and only 5 had concentrations above 550 ng/mL 30 h post-dose. Whether this is clinically significant is unclear and more data in patients who are poorly adherent to darunavir/cobicistat will hopefully emerge in the near future to help clinicians with prescribing the optimal booster in certain complex clinical situations (e.g. suboptimal viral replication suppression).
Notably, measurements of atazanavir PK forgiveness in the presence of cobicistat are similar to those in the presence of ritonavir, 5 where atazanavir terminal elimination half-life was 6.77 h Table 1 . Plasma atazanavir and darunavir steady-state PK parameters, expressed as GM and 95% CI, range and CV, measured over 24 and 72 h PK parameters of 300 mg of atazanavir once daily PK parameters of 800 mg of darunavir once daily Elliot et al.
with cobicistat versus 6.74 h with ritonavir. Darunavir terminal elimination half-life was measured to be 6.35 h with cobicistat versus 6.48 h with ritonavir. While there is no doubt of PI robustness in antiretroviral-naive people living with HIV (PLWH), in patients who are inclined to poor compliance or harbour viral resistance, PK forgiveness knowledge may be particularly important.
However, the clinical significance of our findings is unclear as pharmacodynamic data on what concentrations are needed to ensure long-term viral suppression maintenance in PLWH are unavailable and it is often unclear how delayed a dose needs to be or how many doses can be omitted before efficacy is lost.
A further limitation of the study is that it was conducted in HIVnegative healthy volunteers so as not to impose antiretroviral dose delays in PLWH. Data on potential differences in drug exposure between PLWH and HIV-negative volunteers are controversial but must be taken into consideration. 13 Cobicistat terminal half-life was 4.21 h with atazanavir and 3.62 h with darunavir, therefore shorter than ritonavir terminal half-life with atazanavir (5.03 h) and darunavir (6.30 h), respectively.
Both cobicistat and ritonavir inhibit CYP3A4, thereby reducing the metabolism of concomitantly administered PIs and leading to enhanced drug exposure. 3 Although very similar, the two drugs are not identical and their relationship with the therapeutic agent they enhance may explain concentration decay patterns. Importantly, the rates of decline of both atazanavir and darunavir slightly increased as cobicistat concentrations declined. Cobicistat itself is metabolized by CYP3A4 and, when given with atazanavir, a moderate CYP3A4 inhibitor, 14 it achieves slightly higher concentrations than when co-administered with darunavir, which on the other hand is an inducer of CYP3A4.
14
The inter-individual variability (CV) in atazanavir and darunavir C 24 was 73% and 65% with cobicistat, therefore similar to those previously measured with ritonavir (81% and 62%, respectively). 5 Drug saliva and urine PK elimination profiles mirrored that of plasma, suggesting potential use of these matrices as a marker of adherence/PK forgiveness.
Atazanavir/cobicistat and darunavir/cobicistat were well tolerated, with adverse events limited to expected increases in indirect bilirubin levels during the atazanavir/cobicistat study phase.
In conclusion, our data report the PK forgiveness of atazanavir/ cobicistat and darunavir/cobicistat and contribute to understanding whether drug doses can be delayed or missed and, if so, to what extent. This is important in the context of chronic diseases, where sub-optimal compliance to medications may be common, 15 and therefore within the HIV medicine field, where repercussions of insufficient drug exposure can be serious, since if drug concentrations drop to sub-therapeutic levels after missed doses there is a risk of emergence of drug-resistant HIV strains, which limits future therapeutic options. 
